BIOGEN INC. BIIB

Biogen is focused on three core priorities: commercializing four recently launched first-in-class products (LEQEMBI, SKYCLARYS, ZURZUVAE, QALSODY), reprioritizing its pipeline for key readouts starting in 2026, and redesigning the company to reduce operating expenses and free up resources for growth investments. The company aims to ensure revenue from new launches exceeds the decline in its multiple sclerosis franchise, which saw a $160 million total revenue decline in 2024, but a core pharma business growth when excluding a $247 million contract manufacturing decline.

LEQEMBI is showing steady quarter-on-quarter progress, with ex-U.S. launches contributing significantly, particularly in single-payer systems and cash-pay markets like China. Key catalysts for accelerated launch include FDA approval for IV maintenance dosing (achieved), potential FDA approval for blood-based diagnostics, a PDUFA date of August 2025 for subcutaneous maintenance dosing, and expected launch of subcutaneous initiation in H1 2026. The AHEAD 345 study, fully recruited, is expected to read out in 2028, exploring prevention of Alzheimer's, building on data showing 76% of patients with no or low tau showed no decline and 60% showed clinical improvement at 18 months.

SKYCLARYS for Friedreich's ataxia has doubled patients on treatment in the past year, with global revenue of $102 million in Q4. The company is expanding geographically, expecting approvals in Latin America this year. Patient identification is challenging due to the rare nature of the disease and dispersed patient population (approximately 4,800 patients in the U.S.), but Biogen leverages AI, genetic testing, and multi-channel marketing. Reimbursement is being secured country-by-country, with free goods patients converting to revenue-generating treatments.

ZURZUVAE for depression exceeded expectations, with 80% of prescriptions driven by OB/GYNs, a shift from initial psychiatrist targeting. A European approval is hoped for later this year. QALSODY, while not a major revenue generator, is a breakthrough treatment in ALS, demonstrating neurofilament's utility in predicting drug efficacy and accelerating R&D in the field, making a significant impact on patients' lives.

Biogen's pipeline has been reprioritized to focus on high-conviction programs with potential for future growth, particularly in Alzheimer's and immunology. Key assets include continued investment in Alzheimer's (tau reduction), dapirolizumab (second Phase III initiated) and litifilimab for lupus, and felzartamab for rare kidney diseases (IgAN, PMN) with compelling Phase II results and orphan drug designation in the EU. The company aims for a regular cadence of pivotal readouts and potential launches from this multibillion-dollar portfolio.

Q4 2024 saw 3% revenue growth and 17% non-GAAP diluted EPS growth. Full year 2024 revenue declined 2% to $9.7 billion, with non-GAAP diluted EPS up 12% to $16.47. Free cash flow reached $2.7 billion for FY24. For FY25, total revenue is expected to decline mid-single digits, driven by MS competition, partially offset by new product growth. Non-GAAP R&D and SG&A are projected at $3.9 billion, with operating margin remaining relatively flat. The company expects a $50 million to $100 million impact from Medicare Part D redesign.

Biogen maintains a strong balance sheet with $2.4 billion cash and $3.9 billion net debt, providing significant capacity for internal and external growth. The company seeks to reinforce its pipeline through collaborations (especially pre-GLP tox), early-stage development, and bolt-on acquisitions in immunology and rare diseases. The Royalty Pharma deal for dapirolizumab, providing $200 million in 2025, is seen as a one-off^📎 but a useful model to spread investment risk. Management emphasizes financial discipline and value-enhancing transactions, acknowledging industry pressures^🌐 on commercial returns.